Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAXTER INTERNATIONAL, INC. (BAX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?

On April 7, 2025, a Missouri news outlet reported serious safety issues relating to inaccurate infusion rates with Baxter’s Novum IQ Large Volume Pump (“Novum LVP”), a device used for the controlled delivery of intravenous fluids, based on information from a whistleblower at a local hospital system. The whistleblower claimed that “patients should not be being treated with these pumps. These pumps are not safe.” The report led to the hospital system’s removal of all Novum LVPs.

Then, on April 24, 2025, Baxter sent warning letters to customers regarding a potential underinfusion risk associated with the Novum LVP, disclosing only one serious injury linked to this issue. On July 14, 2025, the Company issued a second warning letter repeating the underinfusion risk along with an additional overinfusion risk, revealing that it had received 79 reports of serious injury and two reports of patient deaths related to the Novum LVP. The FDA subsequently classified these issues as a Class I recall, its most serious designation, reflecting a risk of severe injury or death.

Then, on July 31, 2025, Baxter announced that it was “voluntarily and temporarily [pausing] shipments and planned installations of the Novum LVP” and that the Company was “unable to currently commit to an exact timing for resuming shipment and installation for Novum LVPs.”

On this news, Baxter’s stock price fell $6.24, or 22.4%, to close at $21.61 per share on July 31, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.

Charles Linehan, Esq.,

Glancy Prongay & Murray LLP,

1925 Century Park East, Suite 2100,

Los Angeles California 90067

Email: shareholders@glancylaw.com

Telephone: 310-201-9150 (Toll-Free: 888-773-9224)

Visit our website at www.glancylaw.com.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice

Persons with non-public information regarding Baxter should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.

About Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP (“GPM”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.

With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023459308/en/